SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : InterMune (nasdaq)ITMN
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: IRWIN JAMES FRANKEL who wrote (336)11/5/2002 9:22:26 AM
From: quidditch  Read Replies (1) of 508
 
<Dr. Sjogren and colleagues reported that all patients in the study received the same dose of ribavirin. However, a retrospective analysis demonstrated those patients who received the appropriate dose of ribavirin based on their weight (i.e., greater than 10.6 mg/kg per day) achieved a higher sustained viral response rate in both treatment arms: 75% SVR for the Infergen/ribavirin treated patients and an SVR rate of 52% for the Rebetron arm of the study.>

On the surface, this would appear to suggest that the apparent advantage of Infergen as vs. Rebetron is enhanced when ribavirin dosage is modulated by weight of the patients.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News